Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Omapatrilat is an orally bioavailable angiotensin-converting enzyme (ACE) and neprilysin (NEP) inhibitior (IC50s = 1.7 and 5.3 nM, respectively, for the human enzymes).1 It inhibits the pressor response induced by angiotensin I (Item No. 24737) in normotensive rats (ED50 = 0.07 µmol/kg) and lowers mean arterial pressure (MAP) in sodium-depleted spontaneously hypertensive rats when administered at a dose of 30 µmol/kg.2 Omapatrilat lowers MAP in rats when co-administered with bradykinin (Item No. 37408).3 It also increases tracheal plasma extravasation in a rat model of upper airway angioedema in a dose-dependent manner.4
WARNING This product is not for human or veterinary use.
1. .
2. .
3. .
4. .